Evidence map›Paper›PMID 42808816›Full record

ArticleCNS neuroscience & therapeutics2026

Modulation of Endoplasmic Reticulum Stress via CEBPB: A Potential Molecular Link to Therapeutic Action in Substance Use Disorders.

Cheng Zhang, Hu Li, Ming-Fen Ho

Abstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cheng ZhangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Hu LiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Ming-Fen HoDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-3757-3924

Funding

Alcohol Use Disorder: Acamprosate Pharmacometabolomics-informed PharmacogenomicsR01AA027486 · NIAAA · MAYO CLINIC ROCHESTER · PI Ming-Fen Ho, Richard M. Weinshilboum · 2018 to 2026
$4.0M
Single cell multi-omics of iPSC-derived brain organoids from patients with opioid use disorder: synthetic opioids as molecular probesR01DA057928 · NIDA · MAYO CLINIC ROCHESTER · PI Ming-Fen Ho · 2023 to 2026
$1.7M
Acamprosate pharmacogenomics: iPSC based model of alcohol use disorderK01AA028050 · NIAAA · MAYO CLINIC ROCHESTER · PI HO, MING-FEN · 2019 to 2024
$649k
Mechanistic Insights into Topiramate Response in Comorbid AUD and PTSD: From patients to cellsR01AA033316 · NIAAA · MAYO CLINIC ROCHESTER · PI Ming-Fen Ho, Charles R Marmar · 2026 to 2026
$433k
Brain and Behavior Research Foundation 31329NIAAA NIH HHS AA27486NIAAA NIH HHS AA28050NIAAA NIH HHS AA33316NIAAA NIH HHS K01 AA028050NIAAA NIH HHS R01 AA027486NIAAA NIH HHS R01 AA033316NIDA NIH HHS DA57928NIDA NIH HHS R01 DA057928the Mayo Clinic Center for Individualized Medicine.the Mayo Clinic Research Pipeline K2R Programthe Terrance and Bette Noble Foundation
6 · The paper itself

Abstract

aimsOpioid use disorder remains a major public health crisis in the United States, driven largely by rising overdose deaths from synthetic opioids, such as fentanyl. Emerging population-level evidence suggests that GLP-1 receptor agonists (GLP-1RAs) may reduce overdose risk. However, their underlying molecular mechanisms are not well understood. We investigated the transcriptional effects of fentanyl and GLP-1RAs using human induced pluripotent stem cell (iPSC)-derived forebrain organoids and neurons.

methodsOrganoids were treated with fentanyl, liraglutide, or exenatide, followed by RNA sequencing. We extended these analyses to iPSC-derived neurons exposed to additional therapeutic candidates, including the anticonvulsants topiramate and gabapentin, and the metabolic modulator β-hydroxybutyrate. All compounds were tested at clinically relevant concentrations, and transcriptomic and functional genomic assays were performed.

resultsAcross models and drug classes, we identified modulation of endoplasmic reticulum (ER) stress signaling as a shared molecular mechanism. Fentanyl and GLP-1RAs consistently downregulated ER stress-related genes, with TRIB3 as the most strongly suppressed target. We further identified CEBPB as a key upstream regulator and confirmed reduced CEBPB DNA-binding activity in ER stress-related genes.

conclusionThese findings highlight ER stress modulation as a convergent pathway with potential therapeutic relevance for substance use disorders.

Indexed as

CCAAT-Enhancer-Binding Protein-betaEndoplasmic Reticulum StressSubstance-Related DisordersHumansInduced Pluripotent Stem CellsNeuronsOrganoidsCCAAT-Enhancer-Binding Protein-betabrain organoidsER stressiPSCopioid addictionpharmacotherapy

Identifiers

PMID42808816
PMCPMC13621937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.